Discovery of Biomarkers for Intrinsic Radiation Sensitivity in Cancer Patients
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age21-99
SponsorNational Cancer Centre, Singapore
About this trial
Patients with cancers that are sensitive to radiotherapy treatment and/or patients who have experienced severe acute/ late side effects to radiotherapy will be recruited to the study. Blood and/or matched tumour-normal tissue pairs will be collected. Blood and/or tissue samples will be processed and studied for genetic and biochemical markers that have potential to be used for predicting sensitivity to radiation.
Eligibility criteria
Qualifiers
Patients with severe side effects from radiotherapy
Patients with a type of cancer that is associated with sensitivity to radiotherapy
Disqualifiers
Age of patient must be between 21 (inclusive) and 99 (exclusive)
Trial design
Treatments tested in this trial
- Not listed
Trial groups
No trial groups listed
Sponsors and collaborators
National Cancer Centre, Singapore
Lead sponsor
National Medical Research Council (NMRC), Singapore
Collaborator
Duke-NUS Graduate Medical School
Collaborator
Ferring Pharmaceuticals
Collaborator
ImmunoSCAPE
Collaborator
Decipher Biosciences
Collaborator
Source ClinicalTrials.gov